Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Name: Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
Published: 2025
License: Public Domain

BioNTech SE · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

immunotherapy non-small-cell-lung-cancer

non-small cell lung cancer, second-line treatment, immunotherapy, combination with other investigational agents, bispecific antibody, vascular endothelial growth factor (vegf) a, programmed death-ligand 1 (pd-l1), combination with chemotherapy, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Related documents